CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma

Imagem de Miniatura
Arquivos
art_LONGATTO-FILHO_CD147_immunohistochemistry_discriminates_between_reactive_mesothelial_cells_and_2012.PDF (319.62 KB)
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
PINHEIRO, Celine
SOARES, Tony R.
PEREIRA, Helena
BEDROSSIAN, Carlos
MICHAEL, Claire
SCHMITT, Fernando C.
BALTAZAR, Fatima
Citação
DIAGNOSTIC CYTOPATHOLOGY, v.40, n.6, Special Issue, p.478-483, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Malignant mesothelioma (MM) is a rare form of cancer. Its histopathological diagnosis is very difficult, as it exhibits a number of different appearances that can be misinterpreted as metastatic invasion or atypical hyperplasia. Thus, there is an urgent need to identify adequate markers to distinguish between benign and malignant cells, allowing the implementation of appropriate therapies and, possibly, specific directed therapies. MM, like other tumors, show an increase in glucose uptake, due to high rates of glycolysis, inducing an intracellular overload of acids. In this context, monocarboxylate transporters (MCTs) emerge as important players, by mediating the transmembranar co-transport of lactate with a proton, thereby, regulating pH and allowing continuous glycolysis. Importantly, proper MCT expression and activity depend on its co-expression with a chaperone, CD147, which is associated with poor prognosis in cancer. Twenty-two samples including reactive mesothelial cells, MM, and atypical mesothelial hyperplasias were evaluated for immunoexpression of MCT1, MCT4, and CD147. Expression of these proteins was compared with GLUT1 as a new promising marker for MM. Although MCT isoforms were not differentially expressed in the two types of cytological specimens, CD147, as GLUT1, was almost exclusively expressed in MM. Both MCT1 and MCT4 are not able to discriminate between mesothelial reactive cells and mesothelial malignant cells, while CD147 was able to distinguish these two proliferations. If confirmed, besides being a good marker for identification of MM, CD147 may also be a target for therapeutical strategies in this rare type of tumor. Diagn. Cytopathol. 2012;40:478483. (c) 2012 Wiley Periodicals, Inc.
Palavras-chave
monocarboxylate transporters, CD147, EMMPRIN, malignant mesothelioma
URI
https://observatorio.fm.usp.br/handle/OPI/1585
Referências
  1. BEDROSSIAN CWM, 1992, SEMIN DIAGN PATHOL, V9, P91
  2. Bedrossian CWM, 1998, DIAGN CYTOPATHOL, V19, P131, DOI 10.1002/(SICI)1097-0339(199808)19:2<131::AID-DC14>3.0.CO;2-G
  3. Bedrossian CWM, 1998, DIAGN CYTOPATHOL, V18, P141, DOI 10.1002/(SICI)1097-0339(199802)18:2<141::AID-DC11>3.0.CO;2-L
  4. Benard F, 1998, CHEST, V114, P713, DOI 10.1378/chest.114.3.713
  5. Bertino P, 2009, EXPERT OPIN PHARMACO, V10, P99, DOI [10.1517/14656560802631285 , 10.1517/14656560802631285]
  6. Bougatef F, 2009, BLOOD, V114, P5547, DOI 10.1182/blood-2009-04-217380
  7. Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3
  8. Bury T, 1997, THORAX, V52, P187
  9. Carretta A, 2000, EUR J CARDIO-THORAC, V17, P377, DOI 10.1016/S1010-7940(00)00377-8
  10. Ceresoli GL, 2006, J CLIN ONCOL, V24, P4587, DOI 10.1200/JCO.2006.06.8999
  11. Davidson B, 2004, CLIN EXP METASTAS, V21, P469, DOI 10.1007/s10585-004-3150-2
  12. Filho AL, 2007, DIAGN CYTOPATHOL, V35, P786, DOI 10.1002/dc.20767
  13. Grondin SC, 1999, ONCOLOGY-NY, V13, P919
  14. Hasteh F, 2010, CANCER CYTOPATHOL, V118, P90, DOI 10.1002/cncy.20071
  15. Kato Y, 2007, MODERN PATHOL, V20, P215, DOI 10.1038/modpathol.3800732
  16. Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI [10.2217/fon.09.145, 10.2217/FON.09.145]
  17. Lumb PD, 2004, HISTOPATHOLOGY, V44, P345, DOI 10.1111/j.1365-2559.2004.01844.x
  18. Lyons-Boudreaux V, 2008, ARCH PATHOL LAB MED, V132, P23, DOI 10.1043/1543-2165(2008)132[23:CMVBHU]2.0.CO;2
  19. Nowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234
  20. Pasello G, 2009, CURR DRUG TARGETS, V10, P1235
  21. Pinheiro C, 2009, EUR J CANCER, V45, P2418, DOI 10.1016/j.ejca.2009.06.018
  22. Pinheiro C, 2008, VIRCHOWS ARCH, V452, P139, DOI 10.1007/s00428-007-0558-5
  23. Pinheiro C, 2009, DIS MARKERS, V26, P97, DOI 10.3233/DMA-2009-0596
  24. Pinheiro C, 2008, INT J GYNECOL PATHOL, V27, P568, DOI 10.1097/PGP.0b013e31817b5b40
  25. Pinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x
  26. Quennet V, 2006, RADIOTHER ONCOL, V81, P130, DOI 10.1016/j.radonc.2006.08.012
  27. Ray M, 2009, CHEST, V136, P888, DOI 10.1378/chest.08-2665
  28. Scurry J, 1999, J CLIN PATHOL, V52, P535
  29. Shen J, 2009, AM J CLIN PATHOL, V131, P516, DOI 10.1309/AJCPWFW7O1FVFLKT
  30. Sugarbaker David J, 2010, Expert Rev Respir Med, V4, P363, DOI 10.1586/ers.10.35
  31. van der Most RG, 2006, CANCER GENE THER, V13, P897, DOI 10.1038/sj.cgt.7700935
  32. Walenta S, 2000, CANCER RES, V60, P916
  33. Yan TD, 2009, J CLIN ONCOL, V27, P6237, DOI 10.1200/JCO.2009.23.9640

Coleções
Artigos e Materiais de Revistas Científicas - LIM/14